EPIC Study results1,2
Groundbreaking results of the EPIC (Evaluation of Pimobendan in dogs with Cardiomegaly) Study, the largest veterinary cardiology study in history. Newly published 2018 results now available to complement the 2016 results.
Administration of pimobendan to dogs with Stage B2 myxomatous mitral valve disease (MMVD) and echocardiographic and radiographic evidence of cardiomegaly was shown to result in prolongation of preclinical period by approximately 15 months and to be safe and well tolerated.1FIND OUT MORE
The 2nd EPIC Study publication findings further highlight the benefit of administration of pimobendan to dogs with Stage B2 MMVD and echocardiographic and radiographic evidence of cardiomegaly. Results showed pimobendan treatment significantly reduced heart size and the rate at which cardiomegaly developed.2FIND OUT MORE